Current treatment standards and emerging strategies in mantle cell lymphoma.
about
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignanciesLong-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaMantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Mantle cell lymphoma with features of marginal-zone lymphoma.Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraMolecular targeted approaches in mantle cell lymphoma.Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaIbrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphomaDrug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites.Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.Solitary primary gastric mantle cell lymphoma.Mantle Cell Lymphoma Presenting with Acute Bilateral OphthalmoplegiaProposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
P2860
Q28478591-330A4513-FB41-4533-8072-944EA6482F74Q30279207-4A1DE7FF-ADC1-4499-BE50-78D088EFC59BQ33394767-D9E1EFC4-BAA6-405F-A47C-44036C5CD2ADQ33398818-3F0CD3B1-E81E-4A51-80CB-71AB9FEAD864Q33586239-8B187C36-20E7-4FA8-AD79-30246E95526EQ33917671-82BC7D12-1337-444C-8EB1-92E1A4B563F0Q34415459-FBFD1425-7460-4548-A2B0-3950C9AD5DAEQ34568868-9550FAE4-4BCD-4B05-BE3C-A20C68F53042Q35127368-F4A64606-D626-421B-896A-64F7D327F57FQ35220659-23C55ECA-D4D2-4706-8F0C-9FD9E0968B24Q35525522-B2228D40-3102-42B3-8B8E-3AE5DA2D3869Q35687553-762126E4-D197-41CE-BDF8-332F642607C2Q35835983-D1A8FE6D-05FD-49BE-A9C9-3CEA8494678AQ36028751-94C65F68-03A5-4972-807A-9777A9C9E003Q36163122-D3114469-4482-4A45-A7C2-A3F5BAFC1C22Q36312897-403636A5-BEAB-4EC0-8982-1E919474B0E0Q36469671-5F03BF0A-AA91-4F41-881A-F01A209DCBE2Q37144907-31C5CAE8-6021-4F89-A05F-2DFBA115677FQ37210817-27C72B73-7FD1-40A5-A5BA-08FD483CD328Q37772500-4A9FE950-91CB-4EF6-B76D-11D9055BB865Q37919520-BBC4E43D-582B-4B42-85AC-DF59BEE579EEQ38017138-45228F68-2F0A-4BAF-ADD5-EDE62F69924BQ38098877-E3624733-9F10-48DD-8E66-F85092C66BDEQ38110232-C80F486D-9417-4540-8EA8-DCDADB88CF1EQ38209433-977F3E73-AA8C-4265-8407-7C2F99AD5F86Q38768069-E8F8FC6D-4A4C-480F-895A-35675DD7AF7BQ39269756-6BF52636-0C70-4547-9F33-BA84EE8C7B53Q39352014-CCA35334-9BA9-4993-B74D-F72843A39693Q39375170-EEC279F2-3DE5-4A6F-8905-BCB597269D0AQ39867032-1186BE78-9C1F-4A48-9E55-4027937B8158Q41464443-DE2774C4-D7FA-4DF4-8F4D-007A5854259AQ42592824-F78E09CD-D051-4321-BCF4-2A6C37A231E0Q45124918-C744BA49-E237-4330-BCAA-CAC5B91B62D5Q48206720-39E6A58E-19F7-47E8-9C90-71233EC52196Q54231729-82FAA8EA-9171-4BA4-98F1-2F14E3671C38Q54372017-5F4A0665-8785-4BDE-8729-312423865342Q55035097-D8EA973A-DF41-4702-A9F1-4CAC3C4AD6E1Q55610546-7DA58773-626A-486D-9226-08831FE0D5F0
P2860
Current treatment standards and emerging strategies in mantle cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current treatment standards and emerging strategies in mantle cell lymphoma.
@en
Current treatment standards and emerging strategies in mantle cell lymphoma.
@nl
type
label
Current treatment standards and emerging strategies in mantle cell lymphoma.
@en
Current treatment standards and emerging strategies in mantle cell lymphoma.
@nl
prefLabel
Current treatment standards and emerging strategies in mantle cell lymphoma.
@en
Current treatment standards and emerging strategies in mantle cell lymphoma.
@nl
P2093
P1476
Current treatment standards and emerging strategies in mantle cell lymphoma.
@en
P2093
European MCL Network
Martin Dreyling
Wolfgang Hiddemann
P304
P356
10.1182/ASHEDUCATION-2009.1.542
P577
2009-01-01T00:00:00Z